Is Big Pharma set to corner the American market on medical marijuana?
Category: Culture | Posted on Tue, April, 19th 2011 by THCFinder
The American Independent has previously reported on the growing corporatization of the incipient medical marijuana industry at a time when medical marijuana dispensaries scrabble to hold on to their businesses in the face of a multi-pronged federal crackdown. But there are signs afoot that it just may become ever more corporate if a Big Pharma push to get the U.S. Food and Drug Administration to recognize a cannabis-derived drug is successful.
Last week, British prescription drug manufacturer GW Pharmaceuticals announced a licensing agreement with drug giant Novartis, maker of Ritalin and Excedrin, to begin selling GW’s drug Sativex in markets across Asia, Africa, Oceania and the Middle East. The medication is already available in Britain, where it’s produced and marketed by Bayer, and in Canada and Spain. It’s on the market in those countries as a liquid that patients spray under the tongue and is prescribed primarily for sufferers of multiple sclerosis and cancer.
Sativex: Liquefied marijuana
If the name “Sativex” rings a distant bell, that’s because it’s derived from Cannabis sativa, the scientific name for the plant from which both hemp and marijuana are harvested. It’s an appropriate name because, unlike other cannabinoids produced for recreational and medicinal use (and plagued by side effects not present in natural cannabinoids), Sativex is not a synthetic concoction, but essentially liquefied marijuana. It’s an extract of whole-plant cannabis that includes the psychoactive agent THC as well as cannabidiol (CBD), the chemical thought to be responsible for some of the anti-nausea and cancer-cell-killing effects of medical marijuana.
While the official word from GW is that the THC and CBD balance each other out to provide marijuana’s medicinal effects without an accompanying high, cannabis expert and professor emeritus of psychiatry at Harvard Medical School Dr. Lester Grinspoon has said just upping the dosage would provide the same effects as recreational marijuana.
Early in Sativex’s development, GW hired Dr. Andrea Barthwell as a consultant to sing the drug’s praises, although she’s no longer in the employ of GM. Barthwell was a deputy drug czar under George W. Bush and is the former president of the American Society for Addiction Medicine (ASAM). In a recent ASAM press release, Barthwell denounced medical marijuana but — significantly — only because it was unregulated by the federal government.
- 194,700 Views Category: Odd
- 153,612 Views Category: Fun
- 143,283 Views Category: Culture
- 122,400 Views Category: Culture
- 110,621 Views Category: Medical Marijuana
- 106,411 Views Category: Culture
- 104,547 Views Category: Culture
- 103,185 Views Category: Fun
- 103,170 Views Category: Fun
- 93,731 Views Category: Medical Marijuana